Keppra And Stroke: An Essential Medication For Recovery

Keppra, also known as Levetiracetam, is an anti-epileptic drug that is often used to treat partial onset and generalized seizures. It is also used to prevent post-stroke seizures, particularly in elderly patients. Studies have shown that Keppra is a useful alternative to carbamazepine for preventing post-stroke seizures in terms of efficacy and safety.

Keppra is an anti-epileptic drug

The underlying mechanisms by which Keppra facilitates anti-epileptic and anti-epileptogenic effects are different from classic AEDs. Studies suggest that Keppra primarily works by inhibiting the synaptic vesicle protein 2A. Additional investigations have also revealed that Keppra can inhibit HVA-Ca2 channels and reduce the calcium release from intraneuronal stores.

Keppra has been found to be particularly beneficial for restraining seizures in animal models of spontaneous epilepsy, acute seizures, and status epilepticus. However, its ability to ease epileptogenesis and cognitive dysfunction following status epilepticus remains controversial, with some studies implying favourable outcomes and others reporting no beneficial effects.

Keppra has also been studied for its efficacy in preventing post-stroke seizures. It has been suggested as a first-choice drug in this regard due to its safety and efficacy profiles in clinical studies. Keppra monotherapy is well-tolerated in elderly patients with late-onset post-stroke seizures, and it has been found to be a useful alternative to carbamazepine for preventing post-stroke seizures.

Keppra is used to treat partial onset and generalised seizures

Keppra (levetiracetam) is a prescription drug used to treat certain types of seizures in people with epilepsy. It is an anti-epileptic drug, also called an anticonvulsant, and is available in the form of oral tablets, oral solutions, and intravenous (IV) injections. Keppra is particularly effective in treating partial onset and generalised seizures.

Partial Onset Seizures

Partial onset seizures, also known as focal seizures, occur when the seizure activity is confined to one area of the brain. Keppra is approved by the Food and Drug Administration (FDA) for treating focal seizures in adults and children aged 1 month and older. It can be used as a standalone treatment or in combination with other medications. The typical starting dose for adults and children aged 16 and older is 500 mg, taken twice daily. The dosage may be gradually increased by a doctor every 2 weeks until the optimal amount is reached.

Generalised Tonic-Clonic Seizures

Generalised tonic-clonic seizures, also known as grand mal seizures, are characterised by rapid convulsing or jerking movements along with loss of consciousness. Keppra is often prescribed alongside other seizure medications to treat this type of seizure in certain adults and children aged 6 and older.

How Keppra Works

While the exact mechanism of how Keppra works is not fully understood, it is believed to primarily act by inhibiting the synaptic vesicle protein SV2A. It also modulates Ca2+ currents in neurons, reducing the amplitude of the Ca2+ current. Additionally, Keppra can increase the levels of certain receptors and antioxidant proteins while decreasing pro-oxidant proteins.

Side Effects and Precautions

Keppra may cause mild or serious side effects. Some common side effects include dizziness, drowsiness, unusual tiredness, weakness, and irritability. More serious side effects may include difficulty with balance and coordination, suicidal thoughts or behaviours, and serious skin reactions. It is important to consult a doctor before taking Keppra, especially if one has a history of mental health conditions, kidney disease, or mood disorders.

Keppra has been found to be beneficial in restraining seizures in animal models

Keppra, also known as Levetiracetam, is an anti-epileptic drug used to treat seizures in people with epilepsy. It is beneficial in restraining seizures in animal models of spontaneous epilepsy, acute seizures, and status epilepticus (SE).

Levetiracetam is an anticonvulsant that decreases the number of seizures in patients. It is available in tablet and oral solution forms and is usually taken twice daily. The dosage is based on the patient's medical condition, response to treatment, and weight in the case of children. It is important to note that the drug should not be stopped suddenly, as it may increase the risk of seizures.

Levetiracetam has been found to be particularly effective in animal models, with studies showing that it can restrain seizures and reduce seizure-induced neurodegeneration. In one study, a single dose of Levetiracetam administered 30 minutes after the onset of behavioural SE was sufficient to transiently attenuate seizure activity in animals. Increased doses of the drug were also found to dampen behavioural seizures for prolonged periods.

Another study using acute hippocampal slices from spontaneously epileptic rats suggested that Levetiracetam modulates Ca2+ currents in neurons, as the application of Levetiracetam decreased the amplitude of the Ca2+ current in a concentration-dependent manner. Furthermore, Levetiracetam can abolish the SE-induced rise in brain-derived neurotrophic factors, which are believed to contribute to seizures at higher concentrations.

The efficacy of Levetiracetam as a neuroprotective compound has been examined in several brain injury and neurodegenerative disease prototypes, including brain damage resulting from status epilepticus, spontaneous epilepsy, closed head trauma, subarachnoid haemorrhage, hypoxic-ischemia, and stroke.

Keppra has been found to be a useful alternative to carbamazepine for preventing post-stroke seizures

Keppra (levetiracetam) is an anti-epileptic drug used to treat partial onset and generalized seizures. It is often used in conjunction with other medications to treat certain types of seizures. Keppra is known to be well-tolerated by elderly patients with late-onset post-stroke seizures.

Carbamazepine, on the other hand, is an anticonvulsant used to treat various seizure disorders and relieve nerve pain associated with conditions such as trigeminal neuralgia or diabetic neuropathy. Carbamazepine is also used to treat bipolar disorder and is sometimes prescribed off-label for schizophrenia, attention deficit hyperactivity disorder (ADHD), and substance abuse recovery.

When used in combination with carbamazepine, Keppra may lead to an increased risk of side effects such as dizziness, drowsiness, confusion, and difficulty concentrating. In some cases, it may even cause carbamazepine toxicity, requiring either a reduction in the dose of carbamazepine or the withdrawal of Keppra.

According to a study by Consoli et al. (2012), Keppra has been found to be a useful alternative to carbamazepine for preventing post-stroke seizures, particularly in terms of efficacy and decreased adverse effects. The study compared the efficacy of Keppra and carbamazepine in patients with post-stroke seizures and found no significant difference in the number of seizure-free patients between the two drugs. However, the interval to the first recurrence tended to be longer in patients receiving Keppra. Additionally, Keppra treatment caused significantly fewer side effects than carbamazepine.

In conclusion, Keppra has emerged as a promising alternative to carbamazepine for the prevention of post-stroke seizures. It offers comparable efficacy in controlling seizures while reducing the risk of adverse effects associated with carbamazepine. However, further rigorous studies are needed to confirm these findings and establish the optimal dose, timing, and duration of Keppra treatment for stroke patients.

Keppra is also used to treat spontaneous epilepsy

Keppra is the brand name for the generic drug levetiracetam, an anti-epileptic drug (AED) used to treat seizures in people with epilepsy. It is often used in conjunction with other drugs to treat different types of seizures.

Levetiracetam is approved for use as an add-on therapy for children 1 month of age and older and adults with focal (partial) seizures, myoclonic seizures from juvenile myoclonic epilepsy, and generalized onset tonic-clonic seizures from idiopathic primary generalized epilepsy. It is also approved for use in adults with partial-onset seizures.

The drug works by joining with a protein called SV2A, which is involved with the release of certain chemicals in the brain. This action helps to decrease the frequency of seizures. Levetiracetam has been found to be particularly beneficial in restraining seizures in animal models of spontaneous epilepsy, acute seizures, and status epilepticus.

The dosage of levetiracetam is based on the patient's age, weight, and medical condition. It is usually started at a low dose and gradually increased over a couple of weeks. The recommended dose for adults and teens 16 years and older is 1500 mg twice a day, while the dosage for children is based on their weight and age.

Some of the most common side effects of levetiracetam include loss of strength and energy, mood and behavior changes, drowsiness, dizziness, and unusual tiredness. It is important to note that levetiracetam may also cause serious side effects, such as allergic reactions, coordination problems, and serious dermatological reactions. Therefore, patients should be closely monitored by their healthcare providers while taking this medication.

Frequently asked questions